Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/emmm.202115298 http://scihub22266oqcxt.onion/10.15252/emmm.202115298 35138028!8988202!35138028     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Mol+Med 2022 ; 14 (4): e15298 Nephropedia Template TP {{tp|p=35138028|t=2022. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant |pdf=|usr=}}{{35138028}} gab.com Text A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant JO: EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=35138028 #FOAvip The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC(50) in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID-19 pandemic. Twit Text FOAVip A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant ????EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=35138028 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35138028 #FOAvip English Wikipedia <ref>{{Cite pmid|35138028}}</ref> A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant #MMPMID35138028 Chang YC; Yang CF; Chen YF; Yang CC; Chou YL; Chou HW; Chang TY; Chao TL; Hsu SC; Ieong SM; Tsai YM; Liu PC; Chin YF; Fang JT; Kao HC; Lu HY; Chang JY; Weng RS; Tu QW; Chang FY; Huang KY; Lee TY; Chang SY; Yang PC EMBO Mol Med 2022[Apr]; 14 (4): e15298 PMID35138028show ga The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC(50) in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID-19 pandemic. |*COVID-19[MESH] |Animals[MESH] |Disease Models, Animal[MESH] |Humans[MESH] |Mice[MESH] |Mice, Transgenic[MESH] |Pandemics[MESH] |RNA, Small Interfering/genetics[MESH]A siRNA targets and inhibits a broad range of SARS-CoV-2 infections in(epmc).pdf DeepDyve Pubget Overpricing